Lantern Pharma's Taiwan Approvals for HARMONIC Trial Expand Access to Targeted Lung Cancer Therapy

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with additional IRB approvals expected at two more sites in the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.

The Taiwan approvals mark a significant step for Lantern Pharma as it seeks to expand the trial's geographic reach and accelerate enrollment. Part 2 of the HARMONIC trial will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This extended treatment duration could potentially deepen responses and extend progression-free survival, a critical endpoint in a disease where treatment options after TKI failure are limited.

Preliminary data from the trial showed a median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company notes these findings are preliminary, exploratory, and based on small patient numbers, the trend suggests that completing more cycles may confer a benefit. The L858R mutation is the second most common EGFR mutation in non-small cell lung cancer and is associated with poorer response to standard TKIs compared to exon 19 deletions, underscoring the unmet need for effective therapies in this subgroup.

Lantern Pharma's RADR artificial intelligence and machine-learning platform is designed to identify patients most likely to benefit from its therapies, guiding biomarker-driven clinical development. By leveraging genomic and biological data, RADR aims to transform the cost, pace, and precision of oncology drug development. The HARMONIC trial exemplifies this approach, focusing on a genetically defined patient population that may derive greater benefit from LP-300. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.

For investors, the Taiwan approvals and expanded protocol signal progress in a key clinical program. The ability to enroll patients in multiple regions can speed trial completion and bring a potential therapy to market more quickly. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. To view the full press release, visit https://ibn.fm/CqeDR.

BioMedWire (BioMedWire) is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, as well as article and editorial syndication to 5,000+ outlets. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.